FP 100
Alternative Names: FP-100Latest Information Update: 10 Oct 2023
Price :
$50 *
At a glance
- Originator Northeastern University
- Developer Flightpath Biosciences; Northeastern University
- Class Amides; Antibacterials; Antineoplastics; Furans; Phenols
- Mechanism of Action Peptidyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bacterial infections; Colorectal cancer; Lyme disease
- Research Leptospirosis; Periodontal disorders
Most Recent Events
- 10 Oct 2023 Preclinical trials in Bacterial infections in USA (PO) (Flightpath Biosciences website, October 2023)
- 10 Oct 2023 Preclinical trials in Colorectal cancer in USA (PO) (Flightpath Biosciences website, October 2023)
- 03 Oct 2023 Pharmacodynamics and adverse events data from a preclinical trial in Periodontal disease released by Flightpath Biosciences